Beyond The Printed Page

  1. Daniel Skovronsky – From Grad Student, To CEO, To Big Pharma

    Prior to joining Lilly as SVP of clinical and product development, Daniel Skovronsky, M.D., Ph.D. was CEO of Avid Radiopharmaceuticals — a company he founded while still a graduate student. This article is a prequel to the upcoming feature in our November issue that explores how he built a $300 million company.

  2. Does The Biopharmaceutical Industry Need To Broaden Its Horizons?

    When I interviewed Axovant Sciences CEO David Hung, one of the questions posed was sparked by our discussion of his experience at Pro-Duct Health and his invention of a microcatheter for early detection of ductal breast cancer in women. As he explained his medical device invention, Hung commented, “I don’t want to be just medicines, or just devices, or anything like that.”

  3. What Might Be The Best Predictor Of Future Performance At Axovant Sciences?

    Chief Editor Rob Wright recently conducted an in-person interview with David Hung, formerly of Medivation and current  CEO of Axovant Sciences. Though many may credit the FDA’s approval of Medivation’s Xtandi (enzalutamide) as being the primary driver behind Hung’s rise, Wright argues that there are a number of other predictors that should be evaluated when anticipating future success.

  4. Allergan’s Brent Saunders Shares A Social Contract Secret

    Don't miss this free (all-access) sneak peek of our upcoming September feature article on how Brent Saunders built Allergan’s social contract, a document that may likely define his biopharma legacy. “Over time, as people evaluate my leadership in the role, I hope it is not limited to the social contract," he says.

  5. Coming In September: The Inside Story Of How Allergan Built Its Social Contract

    In the September issue of Life Science Leader, we will feature an article on how Allergan’s Chairman, President, and CEO, Brent Saunders, conceived and created Allergan’s now-famous social contract. You’ll likely be stunned at the approach that was taken.

  6. MMD’s Next Generation Of Leaders

    According to Sanat Chattopadhyay, president of the Merck Manufacturing Division (MMD) and subject of Life Science Leader’s August 2017 feature article, female leaders are going to shape the world in the future.

  7. Successful Transformations Require A Post-Period Of Reflection

    While it is a little early in the Merck Manufacturing Division (MMD) transformation to determine what, if anything, he would have done differently, it is likely Sanat Chattopadhyay will explore this exercise in the near future.

  8. What Would 6 Industry Icons Do Differently If Given The Chance To Be CEO Again?

    When talking with six former pharma CEOs for our Balancing Biopharma’s Bright Future Against Its Tarnished Image — 6 Retired CEOs Share Insights For Today’s Industry Leaders article, we gathered too many great insights to be included within all the pages of a print publication. So, we present that extra content to you here.

  9. Why Would Human Health Companies Want To Partner With Zoetis?

    Scott Brown, D.V.M., Ph.D., VP of external innovation at Zoetis (see our June 2017 feature,) elaborates on some of the challenges faced by the animal health company post IPO in creating research collaborations, as well as why human-health oriented companies might want to consider collaborating with an animal–health-focused company like Zoetis.

  10. IO KOLs Speak On

    More thoughts and comments from cancer immunotherapy experts augment our 2017 immuno-oncology update.